Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02008916 · ClinicalTrials.gov registry record · Phase 3
16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 226
- Enrollment target
NCT02008916 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 226 participants.
The verdict
NCT02008916, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 226 participants
- Enrollment target
Study Summary
The purpose of this study was to generate 16-week efficacy data, as well as up to 3-year efficacy, safety and tolerability data in subjects with active AS despite current or previous NSAID, DMARD and/or anti-TNF therapy.
Interventions
- DRUG Secukinumab
- DRUG Placebo secukinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2014-01-14 |
| Est. Completion | 2017-12-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02008916
The ClinicalTrials.gov registry entry for NCT02008916 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 226 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Secukinumab is the first listed.
NCT02008916 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02008916 about?
NCT02008916 is a clinical study titled "16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients". The purpose of this study was to generate 16-week efficacy data, as well as up to 3-year efficacy, safety and tolerability data in subjects with active AS despite current or previous NSAID, DMARD and/or anti-TNF therapy.
What is the current status of trial NCT02008916?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 226 participants. The study started on 2014-01-14. Estimated completion is 2017-12-11.
What interventions are being tested in trial NCT02008916?
The interventions under investigation include: Secukinumab (DRUG), Placebo secukinumab (DRUG).
Who is sponsoring clinical trial NCT02008916?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.